Bendush C L, Senior S L, Wooller H O
Med J Aust. 1977 Oct 8;2(3 Pt 2 Suppl):22-6. doi: 10.5694/j.1326-5377.1977.tb113913.x.
Tobramycin sulphate, a bactericidal aminoglycoside antibiotic, has been evaluated worldwide in 3,506 patients. Drug-related adverse effects were reported by the investigators in 3.9% of the cases, and included reactions in the nervous system (ototoxicity) in 0.6% and in the kidney in 1.5%. Effects of doubtful relationship to tobramycin occurred in 6.6% of the cases. The effects were usually reversible, although infrequently altered renal or eighth-nerve function appeared to persist in some of the patients. There were no deaths or instances of renal shutdown as a result of tobramycin therapy. Therefore, under the clinical conditions in which it was evaluated, tobramycin appeared to be well tolerated. The association of toxicity with various "risk factors" is discussed.
硫酸妥布霉素是一种杀菌性氨基糖苷类抗生素，已在全球3506例患者中进行了评估。研究人员报告了3.9%的病例出现与药物相关的不良反应，其中0.6%为神经系统反应（耳毒性），1.5%为肾脏反应。6.6%的病例出现了与妥布霉素关系存疑的反应。这些反应通常是可逆的，尽管在一些患者中，肾功能或第八对脑神经功能的改变似乎偶尔会持续存在。没有因妥布霉素治疗导致死亡或肾衰竭的病例。因此，在评估的临床条件下，妥布霉素似乎耐受性良好。文中讨论了毒性与各种“风险因素”的关联。
